WBA Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -7.39% compared to Walgreens Boots Alliance's net margin of 50.24%. Walgreens Boots Alliance's return on equity of -46.98% beat Johnson & Johnson's return on equity of 30.18%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 11.24%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 8.2%. Given that Walgreens Boots Alliance has higher upside potential than Johnson & Johnson, analysts believe Walgreens Boots Alliance is more attractive than Johnson & Johnson.

Walgreens Boots Alliance has a beta of 0.773, which suggesting that the stock is 22.656% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 9.05%. Johnson & Johnson offers a yield of 3.15% to investors and pays a quarterly dividend of $1.24 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Walgreens Boots Alliance quarterly revenues are $38.6B, which are larger than Johnson & Johnson quarterly revenues of $21.9B. Walgreens Boots Alliance's net income of -$2.9B is lower than Johnson & Johnson's net income of $11B. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 4.27x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -7.39% compared to Walgreens Boots Alliance's net margin of -907.48%. Walgreens Boots Alliance's return on equity of -46.98% beat Moderna's return on equity of -29.23%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 11.24%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 95.19%. Given that Moderna has higher upside potential than Walgreens Boots Alliance, analysts believe Moderna is more attractive than Walgreens Boots Alliance.

Walgreens Boots Alliance has a beta of 0.773, which suggesting that the stock is 22.656% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 9.05%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Walgreens Boots Alliance quarterly revenues are $38.6B, which are larger than Moderna quarterly revenues of $107M. Walgreens Boots Alliance's net income of -$2.9B is lower than Moderna's net income of -$971M. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 2.98x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

SunLink Health Systems has a net margin of -7.39% compared to Walgreens Boots Alliance's net margin of -16.93%. Walgreens Boots Alliance's return on equity of -46.98% beat SunLink Health Systems's return on equity of 7.13%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 11.24%. On the other hand SunLink Health Systems has an analysts' consensus of -- which suggests that it could fall by --. Given that Walgreens Boots Alliance has higher upside potential than SunLink Health Systems, analysts believe Walgreens Boots Alliance is more attractive than SunLink Health Systems.

Walgreens Boots Alliance has a beta of 0.773, which suggesting that the stock is 22.656% less volatile than S&P 500. In comparison SunLink Health Systems has a beta of 1.203, suggesting its more volatile than the S&P 500 by 20.282%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 9.05%. SunLink Health Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. SunLink Health Systems pays out -- of its earnings as a dividend.

Walgreens Boots Alliance quarterly revenues are $38.6B, which are larger than SunLink Health Systems quarterly revenues of $7.9M. Walgreens Boots Alliance's net income of -$2.9B is lower than SunLink Health Systems's net income of -$1.3M. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while SunLink Health Systems's PE ratio is 6.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 0.20x for SunLink Health Systems. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of -7.39% compared to Walgreens Boots Alliance's net margin of 5.74%. Walgreens Boots Alliance's return on equity of -46.98% beat UnitedHealth Group's return on equity of 21.74%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 11.24%. On the other hand UnitedHealth Group has an analysts' consensus of $547.65 which suggests that it could grow by 40.04%. Given that UnitedHealth Group has higher upside potential than Walgreens Boots Alliance, analysts believe UnitedHealth Group is more attractive than Walgreens Boots Alliance.

Walgreens Boots Alliance has a beta of 0.773, which suggesting that the stock is 22.656% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.865%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 9.05%. UnitedHealth Group offers a yield of 2.15% to investors and pays a quarterly dividend of $2.10 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Walgreens Boots Alliance quarterly revenues are $38.6B, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Walgreens Boots Alliance's net income of -$2.9B is lower than UnitedHealth Group's net income of $6.3B. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while UnitedHealth Group's PE ratio is 16.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 0.88x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.